Logo image of BIOS.BR

BIOSENIC SA (BIOS.BR) Stock Fundamental Analysis

Europe - Euronext Brussels - EBR:BIOS - BE0974280126 - Common Stock

0.0022 EUR
+0 (+4.76%)
Last: 1/8/2026, 7:00:00 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to BIOS. BIOS was compared to 83 industry peers in the Biotechnology industry. Both the profitability and financial health of BIOS have multiple concerns. BIOS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BIOS has reported negative net income.
In the past year BIOS has reported a negative cash flow from operations.
In the past 5 years BIOS always reported negative net income.
In the past 5 years BIOS always reported negative operating cash flow.
BIOS.BR Yearly Net Income VS EBIT VS OCF VS FCFBIOS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

BIOS's Return On Assets of -100.42% is on the low side compared to the rest of the industry. BIOS is outperformed by 74.70% of its industry peers.
Industry RankSector Rank
ROA -100.42%
ROE N/A
ROIC N/A
ROA(3y)-136.98%
ROA(5y)-104.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOS.BR Yearly ROA, ROE, ROICBIOS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

BIOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOS.BR Yearly Profit, Operating, Gross MarginsBIOS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for BIOS has been increased compared to 1 year ago.
Compared to 1 year ago, BIOS has a worse debt to assets ratio.
BIOS.BR Yearly Shares OutstandingBIOS.BR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100M 200M 300M
BIOS.BR Yearly Total Debt VS Total AssetsBIOS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

BIOS has an Altman-Z score of -17.02. This is a bad value and indicates that BIOS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -17.02, BIOS is doing worse than 80.72% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.02
ROIC/WACCN/A
WACCN/A
BIOS.BR Yearly LT Debt VS Equity VS FCFBIOS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.20 indicates that BIOS may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.20, BIOS is doing worse than 91.57% of the companies in the same industry.
BIOS has a Quick Ratio of 0.20. This is a bad value and indicates that BIOS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.20, BIOS is not doing good in the industry: 91.57% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.2
Quick Ratio 0.2
BIOS.BR Yearly Current Assets VS Current LiabilitesBIOS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.91% over the past year.
EPS 1Y (TTM)90.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIOS.BR Yearly Revenue VS EstimatesBIOS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2019 2020 2021 1M 2M 3M 4M
BIOS.BR Yearly EPS VS EstimatesBIOS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIOS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOS.BR Price Earnings VS Forward Price EarningsBIOS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOS.BR Per share dataBIOS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.01 -0.02 -0.03

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BIOS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOSENIC SA

EBR:BIOS (1/8/2026, 7:00:00 PM)

0.0022

+0 (+4.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27 2025-10-27
Earnings (Next)N/A N/A
Inst Owners1.87%
Inst Owner ChangeN/A
Ins Owners10.94%
Ins Owner ChangeN/A
Market Cap1.44M
Revenue(TTM)N/A
Net Income(TTM)-4.76M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS-0.04
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -100.42%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-136.98%
ROA(5y)-104.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.2
Quick Ratio 0.2
Altman-Z -17.02
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.02%
OCF growth 3YN/A
OCF growth 5YN/A

BIOSENIC SA / BIOS.BR FAQ

What is the ChartMill fundamental rating of BIOSENIC SA (BIOS.BR) stock?

ChartMill assigns a fundamental rating of 0 / 10 to BIOS.BR.


What is the valuation status of BIOSENIC SA (BIOS.BR) stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOSENIC SA (BIOS.BR). This can be considered as Overvalued.


Can you provide the profitability details for BIOSENIC SA?

BIOSENIC SA (BIOS.BR) has a profitability rating of 0 / 10.